Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hodgkin Disease 8Lymphoma, Large-Cell, Anaplastic 6Lymphoma 5Lymphoma, T-Cell, Peripheral 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Non-Hodgkin 3Recurrence 2Neoplasms, Germ Cell and Embryonal 2Lymphoma, B-Cell 2Lymphatic Diseases 2Hematologic Diseases 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Nonseminomatous germ cell tumor 1Neoplasms by Histologic Type 1Neoplasms 1Mycosis Fungoides 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1

Interventions

Vinblastine 1Paclitaxel 1Ifosfamide 1Cisplatin 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Embryonal × Brentuximab Vedotin × Clear all
NCT02689219 2019-12-10

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Indiana University

Phase 2 Terminated
18 enrolled 13 charts
Genitourinary

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Carcinoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡